Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
When it comes to the Treatment and Management of acute myelogenous leukemia (AML), a coordinated, evidence‑based approach is essential for achieving the best possible outcomes. This page is designed for patients, families, and international visitors seeking clear, reliable information about how AML is addressed at Liv Hospital. Each step—from diagnosis to long‑term follow‑up—is explained in plain language, while still reflecting the depth of expertise available at our JCI‑accredited facility. Did you know that AML accounts for roughly 33% of adult leukemias worldwide, and early, aggressive therapy can dramatically improve survival rates? Below you will find a comprehensive overview of the therapeutic pathways, supportive measures, and personalized strategies that define modern AML care.
Our goal is to guide you through the full spectrum of options, helping you understand the rationale behind each choice, the expected timelines, and the resources available to international patients throughout their journey. Whether you are evaluating induction chemotherapy, exploring targeted agents, or considering stem cell transplantation, the information presented here reflects the latest standards and the multidisciplinary expertise of Liv Hospital’s hematology team.
Acute myelogenous leukemia is a rapidly progressing cancer of the blood‑forming cells in the bone marrow. The disease is characterized by the uncontrolled proliferation of immature myeloid blasts, which crowd out normal blood cells and lead to anemia, infections, and bleeding. Early recognition of symptoms such as persistent fatigue, unexplained bruising, frequent infections, and shortness of breath is critical for timely diagnosis.
The diagnostic work‑up typically includes a complete blood count, bone marrow aspiration, cytogenetic analysis, and molecular testing. These investigations not only confirm AML but also identify genetic mutations that influence prognosis and guide therapy selection.
Understanding the biology of AML sets the foundation for a personalized treatment and management plan that aligns with each patient’s risk profile and treatment goals.
Before initiating therapy, patients undergo a thorough risk assessment that categorizes AML into favorable, intermediate, or adverse groups. This stratification is based on cytogenetic abnormalities, gene mutations, and patient‑specific factors such as age and performance status. The risk category directly influences the intensity of chemotherapy, the need for targeted agents, and the consideration of stem cell transplantation.
Accurate risk stratification ensures that the treatment and management plan is both aggressive enough to achieve remission and tailored to minimize unnecessary toxicity.
Conventional chemotherapy remains the backbone of AML therapy. The regimen is divided into two phases: induction, aimed at achieving complete remission, and consolidation, designed to eradicate residual disease and prevent relapse.
The most widely used induction protocol is the “7 + 3” regimen, which combines a continuous infusion of cytarabine for seven days with an anthracycline (such as daunorubicin or idarubicin) administered on the first three days. This approach yields remission rates of 60‑80% in younger patients.
After remission, high‑dose cytarabine (HiDAC) is often administered in multiple cycles, sometimes combined with additional agents like mitoxantrone. For patients with high‑risk disease, consolidation may be followed by allogeneic stem cell transplantation.
Our oncology team monitors response through bone marrow assessments after each cycle, adjusting the treatment and management strategy based on measurable residual disease (MRD) status.
Advances in molecular diagnostics have paved the way for targeted agents that specifically inhibit oncogenic pathways in AML. These drugs are incorporated into the overall therapeutic plan, either alongside standard chemotherapy or as maintenance therapy after remission.
Clinical trials at Liv Hospital provide access to cutting‑edge therapies, ensuring that patients benefit from the latest evidence‑based options. Incorporating these agents into the treatment and management plan can improve remission depth and durability, especially for patients with high‑risk genetic lesions.
Allogeneic hematopoietic stem cell transplantation (allo‑HSCT) offers a potentially curative option for many AML patients, particularly those with adverse risk features. The decision to proceed with transplantation depends on donor availability, patient fitness, and disease status after induction.
Post‑remission therapy may also include maintenance with hypomethylating agents, targeted inhibitors, or low‑dose venetoclax to sustain remission. Ongoing MRD monitoring guides the intensity and duration of these maintenance strategies, forming an integral part of comprehensive treatment and management.
Effective supportive care mitigates treatment‑related complications and improves quality of life. Key components include infection prophylaxis, transfusion support, management of tumor lysis syndrome, and psychosocial counseling.
After completion of active therapy, patients enter a structured follow‑up program that includes regular blood counts, periodic bone marrow examinations, and imaging when indicated. Lifestyle recommendations—balanced nutrition, moderate exercise, and smoking cessation—are reinforced to reduce relapse risk and promote overall health.
Through vigilant monitoring and personalized supportive measures, Liv Hospital ensures that the treatment and management journey extends beyond remission, fostering long‑term survivorship and well‑being.
Liv Hospital combines JCI accreditation, a multidisciplinary oncology team, and a dedicated international patient services department to deliver world‑class care for acute myelogenous leukemia. Our state‑of‑the‑art facilities, access to clinical trials, and personalized coordination of appointments, transportation, interpreter support, and accommodation make us a trusted partner for patients traveling from abroad.
Take the first step toward expert AML care. Contact Liv Hospital today to schedule a consultation, arrange your travel logistics, and begin a tailored treatment and management plan designed for you.
Send us all your questions or requests, and our expert team will assist you.
The induction phase, often using the 7 + 3 regimen (cytarabine plus an anthracycline), aims to bring about a complete remission in the majority of patients. Once remission is confirmed, the consolidation phase follows, typically with high‑dose cytarabine (HiDAC) or other agents to eradicate any remaining leukemic cells. For high‑risk patients, consolidation may be followed by allogeneic stem cell transplantation to provide a curative graft‑versus‑leukemia effect. Throughout both phases, bone‑marrow assessments and measurable residual disease (MRD) testing guide adjustments to therapy. Supportive care measures run in parallel to manage infections, transfusion needs, and treatment‑related toxicities.
After diagnosis, AML patients undergo comprehensive testing that includes karyotyping, fluorescence in‑situ hybridisation, and next‑generation sequencing for mutations such as NPM1, FLT3‑ITD, RUNX1, and ASXL1. These genetic results are combined with clinical variables like age, performance status, and white‑blood‑cell count. The resulting risk category influences treatment intensity: favorable‑risk disease may be treated with standard induction and consolidation, while adverse‑risk disease often requires intensified induction and early consideration of allogeneic transplantation. Accurate stratification helps balance the goal of cure against the risk of excessive toxicity.
In the classic 7 + 3 protocol, cytarabine is administered by continuous intravenous infusion at 100‑200 mg/m² per day for seven days. Concurrently, an anthracycline (daunorubicin 60 mg/m² or idarubicin 12 mg/m²) is given on days 1, 2, and 3. This combination produces remission rates of 60‑80 % in younger, fit patients. After remission, patients transition to consolidation therapy. Modifications of the regimen, such as adding FLT3 inhibitors for FLT3‑mutated disease, are increasingly common to improve outcomes.
For FLT3‑mutated AML, midostaurin is added to standard chemotherapy, while gilteritinib is used in relapsed/refractory settings. IDH1‑mutated disease can be treated with ivosidenib and IDH2‑mutated disease with enasidenib, both of which induce differentiation of leukemic blasts. Venetoclax, a BCL‑2 inhibitor, is combined with low‑dose cytarabine or hypomethylating agents, especially in older or unfit patients. Emerging therapies such as menin inhibitors, CD47 blockers, and antibody‑drug conjugates are being evaluated in clinical trials at Liv Hospital, offering patients access to cutting‑edge options.
Allogeneic hematopoietic stem cell transplantation (allo‑HSCT) provides a potential cure by delivering a graft‑versus‑leukemia effect. Candidates typically include patients with adverse cytogenetics, persistent MRD after induction, or those who relapse after initial therapy. Eligibility depends on donor availability (matched sibling, unrelated, or haploidentical) and the patient’s organ function and performance status. Autologous transplantation may be used in selected cases but lacks the graft‑versus‑leukemia benefit and carries a higher relapse risk. Post‑transplant, maintenance with targeted agents or hypomethylating drugs can reduce relapse.
During periods of neutropenia, patients receive antimicrobial prophylaxis (e.g., fluoroquinolones, antifungals) and close monitoring for fever. Red blood cell and platelet transfusions are given based on defined thresholds to prevent anemia‑related fatigue and bleeding. Electrolyte imbalances and renal function are closely watched to prevent tumor‑lysis syndrome, especially after intensive chemotherapy. Nutritional support, physical therapy, and mental‑health services help maintain quality of life. Liv Hospital’s international patient services also coordinate language interpretation, travel logistics, and accommodation to reduce stress for patients traveling from abroad.
International patients benefit from a single‑point contact who arranges visa assistance, airport transfers, and hotel bookings near the hospital. Multilingual staff provide interpreter services for consultations and consent discussions, ensuring clear communication about diagnosis and treatment plans. The hospital’s JCI accreditation guarantees adherence to global safety standards, and patients have access to clinical trials not available in many home countries. Ongoing coordination includes scheduling follow‑up visits, laboratory testing, and tele‑medicine check‑ins after patients return home, facilitating seamless continuity of care.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
